HRP20110651T1 - Modeli pretraživanja in vivo radi liječenja alzheimerove bolesti i drugih poremećaja povezanih s qpct - Google Patents
Modeli pretraživanja in vivo radi liječenja alzheimerove bolesti i drugih poremećaja povezanih s qpct Download PDFInfo
- Publication number
- HRP20110651T1 HRP20110651T1 HR20110651T HRP20110651T HRP20110651T1 HR P20110651 T1 HRP20110651 T1 HR P20110651T1 HR 20110651 T HR20110651 T HR 20110651T HR P20110651 T HRP20110651 T HR P20110651T HR P20110651 T1 HRP20110651 T1 HR P20110651T1
- Authority
- HR
- Croatia
- Prior art keywords
- glutaminyl cyclase
- mouse
- human animal
- transgenic non
- transgene
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 238000012750 in vivo screening Methods 0.000 title 1
- 230000009261 transgenic effect Effects 0.000 claims abstract 18
- 108700019146 Transgenes Proteins 0.000 claims abstract 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 238000011830 transgenic mouse model Methods 0.000 claims abstract 2
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 claims 21
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 claims 21
- 108010044467 Isoenzymes Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229940123320 Cyclase inhibitor Drugs 0.000 claims 1
- 101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 101000585320 Mus musculus Glutaminyl-peptide cyclotransferase Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Biophysics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88564907P | 2007-01-19 | 2007-01-19 | |
PCT/EP2008/050532 WO2008087197A1 (en) | 2007-01-19 | 2008-01-18 | In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110651T1 true HRP20110651T1 (hr) | 2011-10-31 |
Family
ID=39271322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110651T HRP20110651T1 (hr) | 2007-01-19 | 2011-09-09 | Modeli pretraživanja in vivo radi liječenja alzheimerove bolesti i drugih poremećaja povezanih s qpct |
Country Status (13)
Country | Link |
---|---|
US (1) | US20080200567A1 (es) |
EP (2) | EP2395095A1 (es) |
JP (1) | JP2010516235A (es) |
AT (1) | ATE521711T1 (es) |
AU (1) | AU2008206936B2 (es) |
CA (1) | CA2675192A1 (es) |
DK (1) | DK2121944T3 (es) |
ES (1) | ES2372229T3 (es) |
HR (1) | HRP20110651T1 (es) |
NZ (1) | NZ578513A (es) |
SI (1) | SI2121944T1 (es) |
WO (1) | WO2008087197A1 (es) |
ZA (1) | ZA200904353B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9277737B2 (en) | 2006-09-21 | 2016-03-08 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the QPCTL-gene |
EP2118101B1 (en) * | 2007-03-09 | 2012-09-26 | Probiodrug AG | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
US8227498B2 (en) * | 2007-04-18 | 2012-07-24 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008128981A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
US9656991B2 (en) * | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US9512082B2 (en) * | 2007-04-18 | 2016-12-06 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008128987A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Novel inhibitors |
WO2008128982A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
US8188094B2 (en) * | 2007-04-20 | 2012-05-29 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008297070A1 (en) * | 2007-09-12 | 2009-03-19 | Probiodrug Ag | Transgenic mice |
WO2009090190A1 (en) * | 2008-01-14 | 2009-07-23 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
NZ590658A (en) * | 2008-07-31 | 2012-07-27 | Probiodrug Ag | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases |
US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
DK2606129T3 (en) | 2010-08-19 | 2015-06-29 | Probiodrug Ag | Glutaminyl cyclase crystal structure |
JP2013541938A (ja) | 2010-09-02 | 2013-11-21 | プロビオドルグ エージー | アイソqc関連障害の治療のためのインビボスクリーニングモデル |
US8741614B2 (en) | 2010-11-02 | 2014-06-03 | Probiodrug Ag | Crystal structure of isoglutaminyl cyclase |
WO2013024043A2 (en) | 2011-08-12 | 2013-02-21 | Probiodrug Ag | In vivo screening models for treatment of qc-related disorders |
EP2879719B1 (en) | 2012-08-01 | 2018-07-04 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
US20180318260A1 (en) * | 2015-11-04 | 2018-11-08 | The Scripps Research Institute | Compositions and methods for treating cystic fibrosis |
MC200185B1 (fr) | 2016-09-16 | 2017-10-04 | Coronal Audio | Dispositif et procédé de captation et traitement d'un champ acoustique tridimensionnel |
MC200186B1 (fr) | 2016-09-30 | 2017-10-18 | Coronal Encoding | Procédé de conversion, d'encodage stéréophonique, de décodage et de transcodage d'un signal audio tridimensionnel |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
EP0264166B1 (en) | 1986-04-09 | 1996-08-21 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
JPH07132033A (ja) * | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
KR20110059664A (ko) * | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
MXPA05011861A (es) * | 2003-05-05 | 2006-02-17 | Probiodrug Ag | Uso de efectores de ciclasas de glutamato y glutaminil. |
ATE462432T1 (de) * | 2003-05-05 | 2010-04-15 | Probiodrug Ag | Glutaminylcyclase-hemmer |
ZA200603165B (en) * | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US7304086B2 (en) * | 2004-02-05 | 2007-12-04 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
CA2663635A1 (en) * | 2006-09-21 | 2008-03-27 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
-
2008
- 2008-01-18 NZ NZ578513A patent/NZ578513A/en not_active IP Right Cessation
- 2008-01-18 EP EP11178419A patent/EP2395095A1/en not_active Withdrawn
- 2008-01-18 EP EP08707977A patent/EP2121944B1/en not_active Not-in-force
- 2008-01-18 AT AT08707977T patent/ATE521711T1/de active
- 2008-01-18 AU AU2008206936A patent/AU2008206936B2/en not_active Ceased
- 2008-01-18 WO PCT/EP2008/050532 patent/WO2008087197A1/en active Application Filing
- 2008-01-18 DK DK08707977.8T patent/DK2121944T3/da active
- 2008-01-18 SI SI200830434T patent/SI2121944T1/sl unknown
- 2008-01-18 JP JP2009545932A patent/JP2010516235A/ja active Pending
- 2008-01-18 ES ES08707977T patent/ES2372229T3/es active Active
- 2008-01-18 CA CA002675192A patent/CA2675192A1/en not_active Abandoned
- 2008-01-18 ZA ZA200904353A patent/ZA200904353B/xx unknown
- 2008-01-18 US US12/016,266 patent/US20080200567A1/en not_active Abandoned
-
2011
- 2011-09-09 HR HR20110651T patent/HRP20110651T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200904353B (en) | 2010-09-29 |
AU2008206936A1 (en) | 2008-07-24 |
DK2121944T3 (da) | 2011-10-31 |
JP2010516235A (ja) | 2010-05-20 |
EP2121944A1 (en) | 2009-11-25 |
WO2008087197A1 (en) | 2008-07-24 |
US20080200567A1 (en) | 2008-08-21 |
EP2395095A1 (en) | 2011-12-14 |
SI2121944T1 (sl) | 2011-12-30 |
CA2675192A1 (en) | 2008-07-24 |
ATE521711T1 (de) | 2011-09-15 |
ES2372229T3 (es) | 2012-01-17 |
NZ578513A (en) | 2012-01-12 |
AU2008206936B2 (en) | 2013-03-14 |
EP2121944B1 (en) | 2011-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110651T1 (hr) | Modeli pretraživanja in vivo radi liječenja alzheimerove bolesti i drugih poremećaja povezanih s qpct | |
CN106470545B (zh) | 人源化IL-4和IL-4Rα动物 | |
KR102637590B1 (ko) | 트란스페린 수용체 유전자삽입 모델 | |
RU2674910C2 (ru) | Животные с гуманизированным геном il-15 | |
EP3019005B1 (en) | Mrap2 knockouts | |
JP2011501652A5 (es) | ||
CN106659146A (zh) | 人源化c5和c3动物 | |
CA2092823A1 (en) | Transgenic animals with alzheimer's amyloid precursor gene | |
WO2012071592A2 (en) | A humanized transgenic animal | |
KR20210020018A (ko) | 진행성 골화성 섬유이형성증의 설치류 모델 | |
KR20150126867A (ko) | 조건적 Acvr1 돌연변이체 대립형질을 갖는 설치류 | |
CA2390723A1 (en) | Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight | |
US20050257279A1 (en) | Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism | |
EP2432314B1 (en) | Mouse models carrying a knock-out mutation of the qpctl-gene | |
WO2009142724A2 (en) | Novel gpr101 transgenic mice and methods of use thereof | |
CN113082193B (zh) | 受调节的内分泌特异性蛋白18及其基因的用途 | |
JP2013543978A (ja) | Gpr101トランスジェニックマウス、その使用およびスクリーニング方法 | |
RU2011139297A (ru) | Модель гипер-igе на животных с повышенным переключением класса тяжелых цепей иммуноглобулинов на с эпсилон | |
EP2238252B1 (en) | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene | |
US20130052203A1 (en) | In vivo screening models for treatment of qc-related disorders | |
JP6151502B2 (ja) | 神経芽腫モデルマウス | |
US9277737B2 (en) | Mouse models carrying a knock-out mutation of the QPCTL-gene | |
Stephan5Halle et al. | Demuth et al.(43) Pub. Date: Oct. 31, 2013 | |
WO2003099002A1 (fr) | Mammiferes non humains a modification genetique associee a la cathepsine | |
WO2001082688A1 (en) | Rab GDIα KNOCKOUT ANIMALS |